Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Yuanben (Zhuhai Hengqin) Biotechnology Co. Ltd. currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 2 distinct examiners, showing a lack of examiner overlap in the current portfolio. However, both examiners are located within 1 distinct art unit, which suggests a consistent administrative environment for the company's biotechnology filings. BUNNER, BRIDGET E is identified as the busiest examiner with 1 pending office action, a count shared by the other distinct examiner in the portfolio.
For a practitioner, the fact that 2 distinct examiners are working within 1 distinct art unit means that while individual preferences may vary, the overarching policies of that specific art unit will apply to both pending office actions. This concentration in a single art unit allows for a more unified approach to prosecution than if the actions were spread across multiple units. With 2 pending office actions, the portfolio is small, yet the involvement of 2 distinct examiners requires the practitioner to monitor two separate sets of communications. The focus on Biotechnology & Pharmaceuticals indicates that the subject matter likely involves complex scientific disclosures. The presence of 1 distinct art unit for both pending matters provides a stable baseline for understanding the prior art landscape relevant to this company.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LANDSMAN, ROBERT S | 1 | 81.4% | +13.0% |
| BUNNER, BRIDGET E | 1 | 64.6% | +19.8% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18706832 | VACCINE AGAINST PANCREATIC CANCER, AND MEDICAL USE THEREOF | LANDSMAN, ROBERT S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18706832 | VACCINE AGAINST PANCREATIC CANCER, AND MEDICAL USE THEREOF | LANDSMAN, ROBERT S | — |
| 18706821 | DRUG FOR TREATING AND/OR PREVENTING CANCER AND USE THEREOF | BUNNER, BRIDGET E | — |
| Art Unit | Apps |
|---|---|
| 1647 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18706832 | VACCINE AGAINST PANCREATIC CANCER, AND MEDICAL USE THEREOF | LANDSMAN, ROBERT S | 1647 | §112 | Non-Final OA | — | Pending | May 02, 2024 |
| 18706821 | DRUG FOR TREATING AND/OR PREVENTING CANCER AND USE THEREOF | BUNNER, BRIDGET E | 1647 | §112DP | Non-Final OA | — | Pending | May 02, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialYuanben (Zhuhai Hengqin) Biotechnology Co. Ltd. has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Robert S Landsman has the most, with 1 of Yuanben (Zhuhai Hengqin) Biotechnology Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
